Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
Spanish plasma-derived medicines company Grifols announced with the Andorran government the cancellation of the immunology research center planned for the parish of Ordino. 29 July 2024
The US Food and Drug Administration (FDA) approved Palforzia (peanut [Arachis hypogaea] allergen powder-dnfp] to include initiation of treatment, up-dosing and maintenance in individuals ages one through three years. 27 July 2024
Vividion Therapeutics, a wholly-owned subsidiary of Germany’s Bayer, today announced it will expand its global innovation capabilities with a new research and development (R&D) center and corporate headquarters in San Diego, California. 23 July 2024
US pharm major Eli Lilly on Friday revealed via a social media posting that it has been granted approval from the Chinese National Medical Products Administration (NMPA) to sell tirzepatide for weight loss in the country. 20 July 2024
Novo Nordisk on Friday announced the headline results from a 52-week double-blind Phase II clinical trial with once-daily subcutaneous semaglutide investigating safety and potential for inducing and maintaining weight loss in people with obesity. 25 June 2017
Anyone unfamiliar with pharma might be puzzled by how often the word ‘innovation’ comes up in dialogue, campaigning and marketing messages. 24 June 2017
Astellas Pharma’s suspension as a member of the Association of the British Pharmaceutical Industry (ABPI) is to be extended for a further 12 months with effect from June 24, 2017 in connection with a number of serious breaches of the ABPI Code. 24 June 2017
Portuguese pharma firm BIAL and Japan’s Eisai have announced data from a Phase II study which showed that treatment with Zebinix (eslicarbazepine acetate) had no significant negative impact on attention, information processing and working memory in children with focal-onset epilepsy. 23 June 2017
Republicans have taken the chance to aim further criticism at the Affordable Care Act (ACA) amid US Senate proposals to repeal and replace the act. 23 June 2017
The US Food and Drug Administration has granted drugmaker Novartis approval to market Tafinlar and Mekinist as a combination therapy for patients with metastatic non-small cell lung cancer with BRAF V600E mutation. 23 June 2017
Shares in Danish CNS specialist Lundbeck have fallen 4% on the news that the company, together with development partner Takeda Pharmaceutical, has not succeeded in adding new data to the label for depression therapy Trintellix. 23 June 2017
Danish drugmaker LEO Pharma today announced that it appointed Chris Posner as executive vice president Region US and president and chief executive LEO Pharma Inc. 23 June 2017
Ewopharma revealed yesterday that, as of April 1 this year, it has acquired the rights to commercialize several of Japanese pharma major Eisai's products in 11 countries in Central and Eastern Europe (CEE). 23 June 2017
UK-based Indivior has presented Phase III results from a trial into RBP-6000, an investigational once-monthly therapy for addiction to opioids. 23 June 2017
US fertility treatment specialist OvaScience will cut its workforce and appoint a new chief executive, Christopher Kroeger, in a bid to slow the company’s cash burn rate and focus on key clinical development goals. 22 June 2017
Brazil is one of the most attractive and promising pharmaceutical markets in the world, with all major global pharmaceutical companies operating in the country. 22 June 2017
The New York Times published an analysis of a draft Trump executive order on prescription pricing and innovation. US advocacy group consumer rights Public Citizen reviewed portions of the order text in cooperation with the Times. 22 June 2017
Anthem is pulling out of health insurance exchanges in Wisconsin and Indiana, a decision cheered by Republicans as another harbinger of doom for Obamacare. 22 June 2017
In an Expert View piece, Karl Rotthier, chief executive of sustainable antibiotics company DSM Sinochem Pharmaceuticals, looks at the growing risk posed to pharma's progress and the world's health by resistant bacteria. 22 June 2017
One interesting corollary of Amazon’s recent acquisition of Whole Foods was the effect on pharmacies, which shed about $10 billion in share price value, according to UBS. 22 June 2017
BIO Ventures for Global Health (BVGH), is launching the African Access Initiative (AAI) today at the Biotechnology Innovation Organization (BIO) International Convention at the San Diego Convention Center, to address Africa’s emerging cancer crisis. 22 June 2017
The Australian government is supporting the expansion of community pharmacy programs to help more patients around the country better understand and manage their medications and avoid ill-health, Minister for Health Greg Hunt announced today. 22 June 2017
Shares in Ireland-headquartered Shire are up more than 2% in London, on news that the rare disease specialist has finally received US Food and Drug Administration approval for its long-acting attention deficit hyperactivity disorder (ADHD) therapy. 21 June 2017
Glenmark Pharmaceuticals has entered into a licensing agreement with Boston-based APC Therapeutics for exclusive rights to a small molecule, immuno-oncology compound based on Antigen Presenting Cell (APC) biology. 21 June 2017